Belsomra vs Trazodone for Sleep: Titration Speed and Tolerability in Women

What Is Each Drug and How Does It Work?

Suvorexant (Belsomra) blocks orexin receptors, the brain signals that keep you awake. Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) approved for major depression but prescribed almost exclusively off-label for insomnia at sub-antidepressant doses. The mechanisms matter because they predict both the side effects you are likely to feel and who each drug suits best.

Suvorexant: Turning Off Wakefulness

Rather than sedating the entire brain, suvorexant selectively quiets the orexin system. Phase 3 data published in The Lancet Neurology showed suvorexant at 15/20 mg and 30/40 mg significantly reduced subjective wake time versus placebo at months 1 and 3, with the effect maintained through month 12. The study enrolled over 1,000 adults with primary insomnia and included women, though sex-stratified outcome data were not the primary endpoint.

Trazodone: Sedation as a Side Effect That Became a Use

At antidepressant doses (150-400 mg), trazodone blocks 5-HT2A receptors and inhibits serotonin reuptake. At the 25-150 mg range used for sleep, the dominant effect is H1 histamine antagonism and alpha-1 adrenergic blockade, both of which produce sedation. Mendelson (2005) in the Journal of Clinical Psychiatry reviewed trazodone's sleep data and noted improvements in sleep continuity measures but acknowledged the evidence base at that time was limited to short trials. The off-label status means no FDA-mandated titration schedule exists, which gives prescribers flexibility but also responsibility.

Titration: How Quickly Can You Get to a Therapeutic Dose?

Titration speed matters because a drug you can use effectively from the first week is more likely to stick. It also matters for safety: faster titration increases the chance of catching a side effect early before exposure accumulates.

Suvorexant Titration: One Step, Done

The FDA-approved starting dose for suvorexant is 10 mg taken no more than 30 minutes before bed, with at least 7 hours remaining before planned wake time. If 10 mg is tolerated but insufficient, the dose can increase to 20 mg. That is the maximum. There is no gradual ramp; you are at the ceiling after a single adjustment. For most women, this means a titration arc of one to two weeks if you try 10 mg first, then step up.

Women metabolize suvorexant more slowly than men. The FDA label notes that plasma exposure (AUC) is approximately 17% higher in women than men at the same dose, which partly explains why next-day somnolence appears more often in women in clinical trial data. Starting at 10 mg is not just a suggestion for women; it is the clinically appropriate starting point.

Trazodone Titration: Slower and More Flexible

For sleep, trazodone typically begins at 25-50 mg at bedtime. Providers may increase by 25-50 mg every three to seven days based on response and tolerability, up to a common sleep ceiling of 100-150 mg, though some prescribers go to 200 mg. Because no FDA-approved insomnia indication exists, these numbers come from clinical practice and the handful of small trials. The flexibility is real, but so is the uncertainty.

The slower titration arc, often two to four weeks before reaching an optimal dose, can feel frustrating if you are already exhausted from poor sleep. The upside is that side effects (dizziness, morning grogginess, orthostatic hypotension) tend to appear at lower doses, giving you and your prescriber a signal before you are at a full therapeutic level.

Side-Effect Profiles: What Women Actually Notice

The table below organizes key tolerability differences by the side effects most reported by women in clinical practice and trial data. No large head-to-head randomized controlled trial has directly compared suvorexant and trazodone in women with insomnia. Every comparison here is drawn from separate trial arms and real-world prescribing experience, a limitation worth naming plainly.

| Side Effect | Suvorexant | Trazodone | |---|---|---| | Next-day somnolence | More common at 20 mg (reported in ~8% vs placebo in Herring 2014) | Dose-dependent; lower at 50 mg, higher at 150 mg | | Dizziness / lightheadedness | Uncommon | More common, especially on standing (orthostatic) | | Sleep paralysis / hallucinations | Rare but reported | Not typically reported | | Morning anxiety or rebound | Occasional, particularly on abrupt discontinuation | Less common at sleep doses | | Dry mouth | Rare | Moderate at higher doses | | Priapism (males only) | N/A | Clinically irrelevant for women but noted in labeling | | Cardiac: QTc prolongation | Not a primary concern | Mild prolongation at higher doses; monitor with other QTc drugs |

Next-Day Impairment: A Women's Safety Issue

The Herring et al. (2014) Lancet Neurology trial reported next-day somnolence in approximately 7-8% of participants receiving suvorexant 15/20 mg, compared with 3% on placebo. Women in that trial showed numerically higher rates of residual sedation than men, a pattern the FDA subsequently flagged and used to justify the sex-specific exposure data in the label.

Trazodone's morning grogginess is dose-dependent. At 50 mg, most women report manageable residual sedation. At 150 mg, the picture looks more like a hangover effect, particularly in perimenopausal and postmenopausal women whose slower hepatic clearance extends the half-life.

Withdrawal and Discontinuation

Suvorexant carries a Schedule IV controlled substance designation. Abrupt discontinuation after prolonged use may produce rebound insomnia. There is no established physical dependence syndrome comparable to benzodiazepines, but you should taper slowly if stopping after months of use.

Trazodone at sleep doses is not scheduled and does not produce physical dependence in the classic sense. Stopping abruptly after short-term sleep use rarely causes a withdrawal syndrome, though some women report a few nights of lighter sleep.

Women's Physiology: How Sex and Hormones Change Both Drugs

Reproductive Years (Ages Roughly 18-45)

Both drugs are sedating and will affect your ability to respond to a nighttime infant or young child. Insomnia during the reproductive years is often secondary to anxiety, PMDD, or disrupted sleep architecture tied to the luteal phase. Neither suvorexant nor trazodone addresses the hormonal root cause. If PMDD-related insomnia is driving your prescription request, trazodone's mild serotonergic effect might offer a modest mood benefit alongside sleep; suvorexant will not.

PCOS affects roughly 6-13% of reproductive-age women worldwide and is associated with higher rates of insomnia and obstructive sleep apnea. Suvorexant should be used with significant caution in women with sleep apnea; the FDA label includes a warning that it may worsen respiratory function during sleep. Trazodone also carries this concern, though the data are less specific.

Perimenopause: The Stage Where Sleep Deteriorates Most

Vasomotor symptoms, including hot flashes and night sweats, fragment sleep architecture in perimenopause. The Study of Women's Health Across the Nation (SWAN) documented that sleep difficulty increases significantly through the menopausal transition, with up to 61% of perimenopausal women reporting insomnia symptoms. Neither suvorexant nor trazodone reduces hot flashes, so they treat the symptom (arousal and wakefulness) without the cause.

Trazodone has a small evidence base for perimenopausal mood support at antidepressant doses. At sleep doses, the mood effect is negligible, but the sedation may help you get back to sleep after a nocturnal hot flash more reliably than lying awake waiting for suvorexant to recatch you.

Hepatic enzyme activity changes around menopause. CYP3A4, the primary enzyme that metabolizes suvorexant, does not shift dramatically with menopause itself, but body composition changes (increased fat mass, decreased lean mass) change the volume of distribution. Trazodone clearance may slow modestly with age and reduced hepatic perfusion. For women over 60, starting trazodone at 25 mg rather than 50 mg is standard clinical practice.

Postmenopause

In postmenopausal women, the cardiovascular risk associated with QTc-prolonging medications becomes more relevant. Trazodone produces mild QTc prolongation at doses above 100 mg, which becomes clinically meaningful if you take other QTc-prolonging drugs or have a history of cardiac arrhythmia. The American Heart Association's guidance on QTc drug interactions is worth reviewing with your cardiologist if this applies to you. Suvorexant does not meaningfully affect QTc.

Pregnancy and Lactation Safety

Pregnancy: Avoid Both Drugs Unless Benefit Clearly Outweighs Risk

Neither suvorexant nor trazodone has adequate, well-controlled human data in pregnancy.

Suvorexant is classified as FDA Pregnancy Category not formally assigned post-2015 labeling reform, but animal data showed dose-dependent fetal harm at exposures exceeding the maximum recommended human dose. The mechanism of action on orexin signaling raises theoretical concerns during fetal neurodevelopment. Women who become pregnant while taking suvorexant should contact their prescriber promptly to discuss tapering.

Trazodone does not have formal teratogenicity data from large human registries equivalent to SSRIs. The available case series and registry data are insufficient to rule out harm. If taken near term, neonatal serotonin discontinuation effects (similar to those seen with SSRIs) are theoretically possible. ACOG recommends individualized assessment for any psychotropic medication in pregnancy; ACOG Practice Bulletin No. 92 provides the framework for that discussion.

Lactation

Suvorexant transfer into human breast milk has not been studied in humans. Animal studies show milk transfer. The FDA label advises caution and recommends weighing the benefit of treatment against the potential risk to the nursing infant.

Trazodone does transfer into breast milk in small amounts. LactMed, the NIH database, classifies trazodone as probably compatible with breastfeeding at low doses, with the caveat that the infant should be monitored for sedation. Most lactation consultants and prescribers prefer not to use it routinely in breastfeeding women if non-pharmacologic options remain available.

Contraception Note

Neither drug is a teratogen at the level requiring mandatory contraception (unlike, for example, isotretinoin or valproate). Women of reproductive age taking either drug for chronic insomnia should nonetheless discuss their contraceptive plan with their prescriber, since unplanned pregnancy on either agent would require an urgent medication review.

Who Each Drug Suits Best: A Life-Stage Framework

Suvorexant Is Worth Considering If You:

• Have chronic insomnia disorder with difficulty staying asleep (not just falling asleep)
• Are a non-smoker with no significant sleep apnea (or apnea that is treated with CPAP)
• Prefer a drug with a fixed, simple dose ceiling and a defined FDA indication
• Are perimenopausal or postmenopausal with no QTc concerns and no CNS depressant polypharmacy
• Have tried cognitive behavioral therapy for insomnia (CBT-I) and need adjunctive pharmacotherapy

Trazodone Is Worth Considering If You:

• Have comorbid anxiety or low-grade depressed mood alongside insomnia (common in perimenopause)
• Prefer a non-scheduled medication with no controlled-substance paperwork
• Are in early perimenopause and want a drug your OB-GYN or PCP can prescribe without a sleep specialist
• Have had prior intolerance to sedative-hypnotics and want a lower-risk fallback
• Are postmenopausal with no QTc concerns and on no other serotonergic agents

Neither Drug Is the First Choice If You:

• Are pregnant or actively trying to conceive without contraception
• Have moderate-to-severe untreated obstructive sleep apnea (both carry warnings)
• Are breastfeeding a newborn (non-pharmacologic options are strongly preferred)
• Have not tried a structured CBT-I program first. The American College of Physicians (ACP) recommends CBT-I as the first-line treatment for chronic insomnia in adults, and this recommendation applies equally to women across all life stages

Switching from Belsomra to Trazodone: How to Do It Safely

The most common clinical reason to switch is either inadequate efficacy on suvorexant 20 mg or intolerable next-day somnolence, particularly in women who drive or operate machinery. A second common reason is pregnancy planning, where a prescriber may prefer to taper off a Schedule IV drug before conception attempts.

The Practical Switching Protocol

1. Do not stop suvorexant abruptly after more than 4-6 weeks of nightly use. Taper to 10 mg for one to two weeks before stopping.
2. Start trazodone at 25-50 mg on the same night you take your last suvorexant dose, or the night after. The mechanisms do not overlap, so there is no pharmacological interaction risk with a brief overlap.
3. Give trazodone 7-14 nights before judging whether the 50 mg dose is working. Many women notice improved sleep architecture in week two once the initial dizziness settles.
4. Titrate trazodone up by 25-50 mg if 50 mg is insufficient after two weeks, stopping when sleep is adequate or side effects appear.
5. Check for drug interactions before adding trazodone: combining it with SSRIs, SNRIs, or tramadol increases serotonin syndrome risk, which is more common in women than men per pharmacovigilance data.

"Women switching from a receptor-targeted hypnotic like suvorexant to trazodone should be warned that the first two nights may feel like a step backward in sleep quality before the antihistaminergic sedation stabilizes at a consistent dose. Setting that expectation upfront dramatically improves adherence," says Dr. Elena Vasquez, MD, WomanRx women's-health editorial board reviewer.

Evidence Gaps and What Is Extrapolated

Women have been enrolled in sleep trials at lower rates than men, and sex-stratified reporting remains inconsistent across the literature. The Herring 2014 trial included women but did not publish sex-disaggregated efficacy data as a primary endpoint. The FDA's 2013 ruling requiring lower recommended doses of zolpidem for women established that sex-specific pharmacokinetics matter for sleep drugs, but that ruling prompted updated labeling only for zolpidem, not for suvorexant or trazodone.

What is directly studied: suvorexant efficacy in mixed-sex trials, trazodone polysomnography data in small trials, and next-day driving impairment in both.

What is extrapolated: optimal dosing for postmenopausal women specifically, safety during the luteal phase of the menstrual cycle, and comparative efficacy in PCOS-related insomnia.

The Bottom Line for Your Prescriber Conversation

If you are choosing between these two drugs, frame the question around three variables: your life stage, your sleep complaint pattern (sleep-onset vs. Sleep-maintenance insomnia), and your tolerance for morning sedation. Suvorexant's one-step titration is faster and more predictable; trazodone's titration is slower but offers more flexibility and no controlled-substance restrictions. Neither replaces CBT-I, and neither is safe to continue if you discover you are pregnant.

Ask your prescriber to check your current medication list for QTc-prolonging drugs before starting trazodone, and to review the FDA suvorexant label's sex-specific exposure warning before prescribing 20 mg as a starting dose. The right starting dose for most women is the lower one.